Middle East supply chain disruption
Geopolitical tensions have increased freight costs and transit times; if prolonged, could impact Asia business recovery and margins.
AJANTAPHARMA / Q4-FY26 / risks
Keep the risk register visible.
Ajanta Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
US FDA observations at Paithan plant
Five observations received; while management expects no immediate impact, any escalation could affect filings or existing product supplies.
Price erosion in US generics and Africa institutional
Both markets are tender-driven and competitive; management factors erosion into guidance but unexpected acceleration could pressure margins.
Promoter share pledging by non-executive brothers
Two promoter brothers have increased borrowing against shares for their own businesses, though no pledge on Ajanta shares; could raise governance concerns.